Aarti Pharmalabs Q2 FY27 Results: Consolidated Net Profit ₹71.47 Crore on Total Income of ₹611 Crore
Earnings
Pharmaceuticals
Blacklitt Research3 min read
Photo by CDC on Unsplash (Unsplash License). Illustrative image.
Aarti Pharmalabs said in a filing on 28 Oct 2026 that consolidated total income was ₹610.92 crore and net profit was ₹71.47 crore for the quarter ended 30 Sep 2026. On a standalone basis, total income was ₹613.05 crore and net profit was ₹65.75 crore.
Key highlights
Consolidated
Including its subsidiaries
Total income: ₹610.92 crore, up 46.0% YoY and 13.9% QoQ
Net profit and EPS: ₹71.47 crore, up 248.8% YoY and down 6.1% QoQ; basic EPS ₹7.88
Finance costs: ₹14.95 crore, up 40.1% YoY
Stamp duty provision: ₹2.04 crore, presented as an exceptional item
Standalone
The company on its own, without its subsidiaries
Total income: ₹613.05 crore, up 14.1% QoQ
Net profit and EPS: ₹65.75 crore, down 7.8% QoQ; basic EPS ₹7.25
Other income: ₹0.47 crore, down 84.0% QoQ from ₹2.93 crore
Finance costs: ₹14.95 crore, 2.4% of total income
Summary
Consolidated ₹ crore
Particulars
Q2 FY27
Q2 FY26
YoY
Q1 FY27
QoQ
610.92
418.39
+46.0%
536.25
+13.9%
Revenue from operations
610.45
417.91
+46.1%
535.80
+13.9%
Other income
0.47
0.48
-2.6%
0.45
+4.4%
71.47
20.49
+248.8%
76.14
-6.1%
Finance costs
14.95
10.67
+40.1%
12.88
+16.1%
Depreciation
30.53
24.77
+23.3%
30.03
+1.7%
Tax expense
23.52
8.27
+184.4%
24.92
-5.6%
Net profit margin
11.70%
4.90%
+6.80 pp
14.20%
-2.50 pp
Tax as share of profit before tax
24.8%
28.8%
-3.99 pp
24.7%
+0.10 pp
EPS, basic (₹)
7.88
2.26
+248.7%
8.40
-6.2%
Figures are in ₹ crore; YoY compares with Q2 FY26 and QoQ with Q1 FY27. Click Total income or Net profit to see the rows behind them.
Net profit rose 248.8% from a year earlier, faster than total income, which rose 46.0%. Revenue from operations rose 46.1% and other income fell 2.6%. Against the June quarter, net profit fell 6.1% to ₹71.47 crore while total income rose 13.9% to ₹610.92 crore.
A stamp duty matter is in the notes. The Collector and Additional Superintendent of Stamps, Gandhinagar, by order dated 29 Aug 2026, determined stamp duty of ₹25.00 crore and levied penalties of ₹34.50 crore under the Gujarat Stamp Act, 1958, on an NCLT Ahmedabad Bench order sanctioning the demerger of the pharmaceutical undertaking of Aarti Industries Limited into the company. The company recognised ₹2.04 crore as a provision, presented as an exceptional item for the quarter and half year, and disclosed ₹57.46 crore as a contingent liability, which it considers not probable of outflow.
Profit before tax of ₹94.99 crore is after a share of profit of joint ventures of ₹6.88 crore for the quarter and ₹14.29 crore for the half year. The joint venture is Ganesh Polychem Limited. Tax expense of ₹23.52 crore is 24.8% of that profit before tax.
Finance costs were ₹14.95 crore, up 40.1% from a year earlier, and depreciation was ₹30.53 crore, up 23.3%. In the half year, the company paid dividends of ₹18.14 crore.
Standalone ₹ crore
Particulars
Q2 FY27
Q2 FY26
YoY
Q1 FY27
QoQ
613.05
420.44
+45.8%
537.52
+14.1%
Revenue from operations
612.58
416.86
+47.0%
534.59
+14.6%
Other income
0.47
3.58
-86.9%
2.93
-84.0%
65.75
30.93
+112.6%
71.31
-7.8%
Finance costs
14.95
10.66
+40.2%
12.87
+16.2%
Depreciation
30.53
24.77
+23.3%
30.03
+1.7%
Tax expense
23.52
8.27
+184.4%
24.92
-5.6%
Net profit margin
10.73%
7.36%
+3.37 pp
13.27%
-2.54 pp
Tax as share of profit before tax
26.3%
26.0%
+0.31 pp
25.9%
+0.45 pp
EPS, basic (₹)
7.25
2.59
+179.9%
7.87
-7.9%
Figures are in ₹ crore; YoY compares with Q2 FY26 and QoQ with Q1 FY27. Click Total income or Net profit to see the rows behind them.
Standalone net profit was ₹65.75 crore, down 7.8% from the June quarter, while total income rose 14.1% to ₹613.05 crore. Other income was ₹0.47 crore, down 84.0% from ₹2.93 crore in the June quarter.
Standalone tax expense of ₹23.52 crore is 26.3% of profit before tax of ₹89.27 crore. Standalone finance costs of ₹14.95 crore are 2.4% of total income this quarter, and depreciation was ₹30.53 crore.
The standalone statement shows the same ₹2.04 crore provision for the stamp duty matter as an exceptional item for the quarter and half year.
Inference
A change in finance leadership is reported. Piyush Lakhani resigned as Chief Financial Officer and Key Managerial Personnel to pursue an alternate career opportunity outside the organization, and is relieved from services at close of business on 30 Oct 2026. Vibha Thakkar is appointed Chief Financial Officer and Key Managerial Personnel with effect from 31 Oct 2026, on the recommendation of the Nomination and Remuneration Committee and Audit Committee. She is a chartered accountant with over 18 years of experience, most recently AVP-Finance & Accounts at NOCIL Limited.
The stamp duty matter remains open. The writ petition in the Gujarat High Court is pending and no interim order has been passed. The filing does not say when a decision is expected or what the outcome will be.
Create a free account to read the rest of this article and the analysis that follows.
By continuing you agree to our Terms and Privacy Policy, and to receive updates from Blacklitt by email. You can unsubscribe anytime.
Disclaimer:
The information available on this article is provided for education and informational purposes only. It does not constitute or provide financial, investment or trading advice and should not be construed as an endorsement of any specific stock or financial strategy in any form or manner. We do not make any representations or warranties regarding the quality, reliability, or accuracy of the information provided. This website may contain links to third-party content. We are not responsible for the content or accuracy of these external sources and do not endorse or verify the information provided by third parties. We are not liable for any decisions made or actions taken based on the information provided on this website.
AARTIPHARMAarti Pharmalabs Ltd.
